AlphAIalphai — Financial news for AI agents
SEC EDGARAUG 62 min read$PFE

DAMICO JENNIFER B. sold $83K of PFE

DAMICO JENNIFER B. (SVP & Controller) sold 3,278 shares of PFIZER INC (PFE) at $25.40 on 2026-08-05.

Original reporting
SEC EDGAR · DAMICO JENNIFER B.
Published Aug 6, 2026, 3:26 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 6, 2026, 3:45 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About alphai AI DeskScoring methodologyReport an issue
alphai market briefInsider activity
Primary signal
$PFE
Neutral
high confidence
Mentioned
$PFE
Relevance
3/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$PFENeutralLow
01

Why it matters

Traders may note insider selling as a sentiment datapoint, but the disclosure lacks any fundamental trigger (no earnings, guidance, deal, or regulatory update).

02

Market read

A routine insider open-market sale is disclosed; it is unlikely to change the investment thesis absent other catalysts.

03

What to watch

The article provides only the sale details, not motivations, tax events, or whether other insiders executed offsetting buys.

Relevance 3/10Novelty 3/10Timing: filed 2026-08-06, transaction dated 2026-08-05

Background

The article is an SEC Form 4 insider transaction disclosure for Pfizer.

Company-level read

Ticker impact

$PFENeutralHigh confidence
Context

Pfizer Form 4 shows SVP & Controller Jennifer B. Damico sold 3,278 shares at $25.40 on 2026-08-05, totaling $83,261.20.

Expected impact

Likely minimal near-term impact on PFE price; treat as low-signal insider activity.

Evidence & confidence

The filing discloses a single officer sale size and price, without any accompanying corporate event, guidance change, or regulatory action.

Market effects

Sector

No clear read-through to pharma sector fundamentals from a single officer sale.

Regional

None indicated.

Global

None indicated.

Counterpoint

What could challenge this read

Insider sales can be planned for liquidity or diversification; absence of a 10b5-1 plan does not automatically imply negative information.

Key entities

  • issuer
    Pfizer Inc

    Subject of the Form 4 insider transaction disclosure.

  • insider
    Jennifer B. Damico

    SVP & Controller who sold 3,278 shares at $25.40 on 2026-08-05.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

PFE insider trading history →

Related articles

SEP 4
$PFEMedAI 8/10

Pfizer’s Stock Has Been Crushed—Is Its 6% Dividend Finally Worth Buying?

Pfizer (PFE) stock has declined 19.19% over five years, resulting in a 6% dividend yield. The company paid $9.77 billion in dividends in 2025, with a thin cash cushion. CEO Albert Bourla assured dividend maintenance but ruled out near-term hikes. Q2 2026 adjusted EPS was $0.77, beating estimates, with full-year guidance of $2.80-$3.00.

aol.com3 min
SEP 4
$PFEHighAI 8/10

19 vaccine approved by US FDA

The US FDA approved Pfizer and BioNTech’s XFG-adapted COVID-19 vaccine for adults 65+ and high-risk individuals 5-64. The approval is based on clinical, real-world, and manufacturing data. The vaccine targets the XFG variant and will be available in the US from autumn 2026.

pmlive.com2 min
SEP 2
$MRNAMed

Updated COVID-19 vaccines are coming this fall. Will insurance cover them?

The FDA approved updated COVID-19 vaccines from Moderna, Pfizer, and Sanofi for the fall season. Health insurers, per AHIP, will cover these vaccines, as required by the Affordable Care Act. Uninsured individuals may access free vaccines through state or federal programs. The vaccines target specific high-risk groups, with recommendations from the AAFP and CDC.

abcnews.com3 min
SEP 2
$PFEHighAI 9/10

FDA Approves Updated COVID-19 Vaccines for 2026-2027

The FDA approved updated 2026-2027 COVID-19 vaccines from Pfizer-BioNTech, Moderna, and Novavax targeting the JN.1-lineage XFG variant. Approvals cover high-risk populations, including adults 65+ and those with underlying conditions. Pfizer and Moderna's mRNA vaccines and Novavax's protein-based vaccine are now authorized for distribution.

respiratory-therapy.com2 min